MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer's drug Aduhelm than it normally would for a Part B drug.
For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm
MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer’s drug Aduhelm than it normally would for a Part B drug.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
